Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
  • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
  • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
  • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
  • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
  • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
  • A61K9/7061—Polyacrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/42—Oxazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

• the present invention relates to new pharmaceutical compositions comprising derivatives of 2-isoxazoles-8-aminotetralins.
• compositions could be used for topical administration comprising a derivative of 2-isoxazole-8-aminotetraline.
• an adhesive polymer system or "patch", term of English origin
• the invention therefore relates to a matrix or reservoir pharmaceutical composition for topical administration comprising at least one 2-isoxazole-8-aminotetralin derivative in a therapeutically effective amount and one or more pharmaceutically acceptable excipients.
• 2-isoxazole-8-aminotetralin derivative is meant in particular all those which have been described in the patents cited above.
• Said 2-isoxazole-8-aminotetralin derivative can be in the form of a free base or in the form of a pharmaceutically acceptable salt.
• pharmaceutically acceptable salt means in particular addition salts of inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide and nitrate or organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methane sulfonate, p-toluenesulfonate, pamoate, oxalate and stearate.
• the salts formed from bases such as sodium or potassium hydroxide.
• the 2-isoxazole-8-aminotetralin derivative will be in the form of a pharmaceutically acceptable salt.
• a patch will be used which will contain in its matrix the derivative of 2-isoxazole-8-aminotetralin.
• Said patch can be presented in different forms: reservoir; matrix on adhesive polymer; DIA patch (i.e. "Drugln Adhesive" in English), in other words patch in the form of a single adhesive polymer layer in which the active principle is distributed; or finally multilamellar patch.
• DIA patch i.e. "Drugln Adhesive” in English
• DIA patch i.e. "Drugln Adhesive” in English
• patch in the form of a single adhesive polymer layer in which the active principle is distributed
• multilamellar patch multilamellar patch.
• the excipients can be polymers or copolymers or else simply monomers.
• the composition will incorporate adhesive polymers or copolymers such as elastomers of the polyethylene vinyl acetate (EVA) type, polymers or copolymers based on styrene, polyisobutylene or acrylic polymers or copolymers, and in particular methacrylic copolymers.
• EVA polyethylene vinyl acetate
• plasticizers include, for example, tributylacetyl citrate or any other pharmaceutically acceptable plasticizer known to those of skill in the art.
• a gelling agent is present in a proportion preferably of 20 to 50%.
• the gelling agents which can be used for the topical compositions according to the invention notably comprise the cellulose derivatives, and in particular hydroxypropyl-methyl cellulose (HPMC), or the poloxamers (that is to say copolymers of polyethylene and of propylene glycol), in particular Lutrol ® F 127 (BASF).
• the topical compositions according to the invention can also comprise other excipients in order to facilitate the transdermal passage of the 2-isoxazole-8 derivative.
• aminotetralin in other words transdermal absorption promoters, and in particular alcohols or polyols such as ethanol, 1,3-butanediol, polyethylene glycols (PEG), fatty acid esters, in particular triglycerides of caprylic and capric acids and in particular Miglyol® (H ⁇ ls, Mari, Germany), or other surfactants or amphiphilic substances known to those skilled in the art.
• ethanol or fatty acid esters such as Miglyol® are preferred.
• compositions according to the invention may also comprise, where appropriate and in particular when they are in the form of an aqueous gel, a preservative, preferably propylene glycol. Likewise, they may also include an antioxidant agent, and in particular ethylenediaminetetracetic acid (EDTA).
• a preservative preferably propylene glycol.
• EDTA ethylenediaminetetracetic acid
• a topical pharmaceutical composition according to the invention will preferably comprise between approximately 5 and 80 mg, more preferably between approximately 5 and 50 mg, and more particularly between approximately 5 and 20 mg, for example approximately 5 mg of 2-isoxazole-8 derivative. -aminotetralin, this mass being calculated relative to said derivative in the form of the free base. This dose should make it possible to ensure the daily treatment of a patient, but it is up to the attending physician to decide ultimately how often to apply.
• the pH of the topical pharmaceutical composition according to the invention will preferably be between 7 and 9.5, and more preferably between 8 and 9.5 when the derivative of 2- isoxazole-8-aminotetralin is in the form of the free base.
• the pH of the topical pharmaceutical composition according to the invention will preferably be between 5 and 7.5, and more preferably between 5.5 and 7.
• the invention also relates to the use of a derivative of 2-isoxazole-8-aminotetralin, and in particular of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) -N, N-diisopropyl- 2-naphthalenamine, for the manufacture of a medicament for transdermal administration, in particular in the treatment of irritable bowel syndrome.
• a derivative of 2-isoxazole-8-aminotetralin and in particular of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) -N, N-diisopropyl- 2-naphthalenamine
• a patch intended for the transdermal administration of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) - N, N-diisopropyl-2-naphthalenamine was prepared from a copolymer of methacrylate and ammonioalkyl according to the procedure described below.
• the solution obtained is then spread at a rate of 100 g / m 2 on a carrier sheet (15 ⁇ m thick, Revtrans MN, Tricon GmbH, Freiburg-im-Breisgau, Germany).
• the polymer layer is dried for 10 minutes with a flow of 1500 m 3 / h of air at 60 ° C (recycling with 80 m 3 / h of exhaust).
• the polymer obtained can then be cut to form patches with an area of approximately 15 cm 2 , which can be used to dispense a daily dose.
• a patch intended for the transdermal administration of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) - N, N-diisopropyl-2-naphthalenamine was prepared from a copolymer of methacrylate and of ammonioalkyl according to the mode procedure described in Example 1, except that 10 g of Miglyol® 812 (Huis, Mari, Germany) were added in portions between the addition of 1,2,3,4-tetrahydro-8- (5- isoxazolyl) -N, N-diisopropyl-2-naphthalenamine and the addition of succinic acid and that after this addition of Miglyol® 812, the mixture was stirred for an additional 20 minutes.
• Miglyol® 812 Huis, Mari, Germany
• a patch intended for the transdermal administration of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) - N, N-diisopropyl-2-naphthalenamine was prepared from a copolymer of methacrylate and of ammonioalkyl according to a method procedure similar to that described in Example 1. except that the 20 g of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) -N, N-diisopropyl-2-naphthalenamine are replaced by 22.44 g of 1,2,3,4-tetrahydro- 8- (5-isoxazolyl) -N, N-diisopropyl-2-naphthalenamine hydrochloride.
• a gel intended for the transdermal administration of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) - N, N-diisopropyl-2-naphthalenamine was prepared from an aqueous dispersion of hydroxypropyl -methyl cellulose (HPMC), according to the procedure described below (to prepare 100 g of gel).
• HPMC hydroxypropyl -methyl cellulose
• composition of the gel is composition of the gel:
• solution I An aqueous solution (solution I) is first prepared by dissolving 3 g of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) -N, N-diisopropyl-2-naphthalenamine hydrochloride in 4 g of propylene glycol and 8 g of purified water. The solution thus obtained is then filtered on a 10 ⁇ m filter. We obtain solution I.
• aqueous dispersion of HPMC is then prepared under vacuum by mixing 30 g of HPMC with 55 g of purified water. Still with stirring, the mixture is heated to a temperature of 50-60 ° C., for 20 min, until a gel of homogeneous appearance is obtained (gel II).
• Solution I is added in portions to gel II, then the mixture is left for 20 min still under vacuum, with stirring and at 50-60 ° C, to obtain 100 g of drug.
• the drug is homogenized by passing it through a die (homogenizer to die).
• the gel thus obtained can be divided into tubes.
• Each application will consist of a hazelnut of approximately 1 g.
• a gel intended for transdermal administration of 1,2,3,4-tetrahydro-8- (5-isoxazolyl) - N, N-diisopropyl-2-naphthalenamine was prepared, according to the procedure described in Example 4 except that was used poloxamer Lutrol ® F 127 (BASF) as gelling agent.

Landscapes

• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=9544866

Family Applications (1)

Country Status (7)

Families Citing this family (15)

Family Cites Families (9)

• 1999
  • 1999-04-26 FR FR9905268A patent/FR2792529B1/fr not_active Expired - Fee Related
• 2000
  • 2000-04-26 JP JP2000613435A patent/JP2002542290A/ja active Pending
  • 2000-04-26 CA CA002370581A patent/CA2370581A1/fr not_active Abandoned
  • 2000-04-26 WO PCT/FR2000/001099 patent/WO2000064444A1/fr active Search and Examination
  • 2000-04-26 EP EP00922748A patent/EP1173173A1/de not_active Withdrawn
  • 2000-04-26 AU AU43044/00A patent/AU4304400A/en not_active Abandoned
  • 2000-04-26 US US10/069,804 patent/US6685959B1/en not_active Expired - Fee Related

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events